ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "anti-TNF therapy"

  • Abstract Number: 1242 • 2019 ACR/ARP Annual Meeting

    Impact of Smoking Status on Remission in Hidradenitis Suppurativa

    Amil Agarwal 1, Marissa Mangini 1, Derek Jones 1, Catherine Hood 1, Richard Amdur 1 and Victoria Shanmugam2, 1The George Washington University School of Medicine and Health Sciences, Washington, DC, 2George Washington University, Georgetown, DC

    Background/Purpose: Hidradenitis Suppurativa (HS) is an inflammatory disease of the apocrine sweat glands characterized by recurrent abscessing inflammation. The molecular drivers of HS are poorly…
  • Abstract Number: 2297 • 2019 ACR/ARP Annual Meeting

    Anti-TNF-α Exposure During Pregnancy: Impact on the Neonate’s Immune System

    Yiyi Luo 1, Andrea Pluma 2, Raul Castellanos-Moreira3, Estefania Moreno 4, Nuria Baños 5, Sebastian DC Rodriguez-Garcia 6, Angela Deyà-Martínez 1, Ana Pilar Garcia-Garcia 1, Mireia Torres 7, Dolors Grados 8, Manel Casellas 9, Manel Juan 1, Ana Esteve-Sole 1 and Laia Alsina 10, 1Immunology Department. Center for Biomedical Diagnosis. Hospital Clínic of Barcelona IDIBAPS. Barcelona University. Barcelona. Functional unit of Clinical Immunology HSJD-HCP.Universidad de Barcelona. Pediatric Investigation Institute SJD, Barcelona, Spain, 2Hospital Universitari Vall d'Hebron, Barcelona, Spain, 3Rheumatology Department. Hospital Clínic Barcelona, Barcelona, Catalonia, Spain, 4Rheumatology Department. Vall d'Hebron University Hospital, Barcelona, Spain, Barcelona, Spain, 5Matern-Infantile Department, Hospital Clínic of Barcelona. Barcelona. Spain, Barcelona, Spain, 6Arthritis Unit. Rheumatology Department. Hospital Clinic of Barcelona. Barcelona. Spain, Barcelona, Spain, 7Neonatology Department. Vall d'Hebron University Hospital, Barcelona, Spain, Barcelona, Spain, 8Hospital d'Igualada, Barcelona, 9Hospital Universitari Vall d'Hebron, Barcelona, 10Hospital Sant Joan de Déu, Barcelona, Spain

    Background/Purpose: Up to half of pregnant patients with rheumatic diseases experience disease activity which can increase the risk of pregnancy complications and poor disease outcomes. Treatment…
  • Abstract Number: 419 • 2019 ACR/ARP Annual Meeting

    Real-World Evidence on the Early Effects of Golimumab on Work Productivity and Activity Impairment in Patients with Spondyloarthritis: Interim Results from a Prospective, Observational Study

    Panagiotis Athanassiou 1, Ioannis Kallitsakis 2, Gkikas Katsifis 3, Anastasios Kotrotsios 4, Georgios Vosvotekas 5, Panagiotis Georgiou 6, Andreas Bounas 7, Yiannis Haratsis 8, Evangelia Petrikkou 8 and Dimitrios Vassilopoulos9, 1General Hospital of Thessaloniki “Agios Pavlos”, Thessaloniki, Greece, 2Private Practice, Chania, Greece, 3Naval Hospital of Athens, Rheumatology Clinic, Athens, Greece, 4Private Practice, Karditsa, Greece, 5Euromedica General Clinic of Thessaloniki, Rheumatology Clinic, Thessaloniki, Greece, 6General Hospital of Patras “Agios Andreas”, Patras, Greece, 7Olympion therapeutirion, Patras, Greece, 8Merck Sharp & Dohme Pharmaceutical, Industrial and Commercial S.A, Medical Affairs, Athens, Greece, 92nd Department of Internal Medicine and Laboratory, National and Kapodistrian University of Athens, School of Medicine, Hippokration General Hospital, Athens, Greece

    Background/Purpose: There are limited real life data regarding the effect of golimumab on work productivity and activity impairment in rheumatic diseases. The aim of our…
  • Abstract Number: 1397 • 2019 ACR/ARP Annual Meeting

    Comparative Effectiveness of Tocilizumab in Combination with Methotrexate versus Tumor Necrosis Factor Inhibitors (TNFis) in Combination with Methotrexate in Patients with Rheumatoid Arthritis with Prior Exposure to TNFis

    Dimitrios Pappas1, Taylor Blachley 2, Steve Zlotnick 3, Jennie Best 3, Kelechi Emeanuru 2 and Joel Kremer 4, 1Columbia University, New York, NY, 2Corrona, LLC, Waltham, MA, 3Genentech, Inc., South San Francisco, CA, 4Albany Medical College and The Center for Rheumatology; Corrona, LLC, Albany, NY

    Background/Purpose: Clinical studies have demonstrated the efficacy of tocilizumab (TCZ) administered with methotrexate (MTX) in improving rheumatoid arthritis (RA) disease activity in patients who have…
  • Abstract Number: 2359 • 2019 ACR/ARP Annual Meeting

    High Body Mass Index Shortens Retention of Tumor Necrosis Factor-α Blocker Treatment in Rheumatoid Arthritis

    Ori Elkayam 1, Merav Lidar 2, Tatiana Reitblat 3, Devy Zisman 4, Alexandra Balbir-Gurman 5, Odelia Kakakian 1, Tanya Meshiach 5, Ronit Almog 6 and Ofir Elalouf1, 1Tel Aviv Medical Center, Tel Aviv, Israel, 2Rheumatology Unit Sheba Medical Center, Ramat Gan, Israel, 3Barzilai Medical Center, Ashkelon, Israel, 4Carmel Medical Center, Haifa, Israel, 5Rambam Medical Center, Haifa, Israel, 6the7Epidemiology and Biostatistics Unit, Rambam Health Care Campus, Haifa, Israel

    Background/Purpose: The primary objective was to evaluate the effect of body mass index (BMI) on tumor necrosis factor α (TNF-α) blockers (including etanercept, infliximab, adalimumab…
  • Abstract Number: 464 • 2019 ACR/ARP Annual Meeting

    Continuous Decrease in Serum RF Titer During Anti-TNF Therapy Was Associated with Suppression in Progression of RA Joint Damage

    Takayoshi Owada1, Kazuhiro Kurasawa 1, Yuta Takamura 1, Toshiyuki Miyao 1, Ayae Tanaka 1, Ryutaro Yamazaki 1, Satoko Arai 1, Reika Maezawa 1 and Masafumi Arima 1, 1Dokkyo Medical University, Mibu-machi, Shimotsuga-gun, Tochigi, Japan

    Background/Purpose: A number of studies have investigated the association between serum RF and joint damage in early and established RA patients, and positive and high-titer…
  • Abstract Number: 1410 • 2019 ACR/ARP Annual Meeting

    Cycling of Tumor Necrosis Factor-α (TNF-α) Inhibitors versus Switching to Different Μechanism of Αction in Rheumatoid Arthritis Patients with Inadequate Response to TNF-α Inhibitor: A Bayesian Network Meta-analysis

    Alberto Migliore1, Giuseppe Pompilio 2, Davide Integlia 2, Joe Zhuo 3 and Evo Alemao 4, 1Unit of Rheumatology Ospedale S. Pietro Fatebenefratelli, Rome, Italy, 2Isheo Srl, Rome, Italy, 3Bristol-Myers Squibb, Princeton, NJ, 4Bristol-Myers Squibb, Princeton

    Background/Purpose: TNF inhibitors are a common treatment for rheumatoid arthritis (RA), but there is no best practice for when a specific TNF inhibitor stops working1.…
  • Abstract Number: 2364 • 2019 ACR/ARP Annual Meeting

    Multi-center Analyses on 518 Cases with Rheumatoid Arthritis Developing Lymphoproliferative Disorders (RA-LPD): The Prognostic Factors and the Influence of Anti-rheumatic Drugs on LPD Development

    Yoshihiko Hoshida1, Shiro Ohshima 2, Yukihiko Saeki 3, Masao Katayama 4, Tomoya Miyamura 5, Atsuahi Hashimoto 6, Shinji Higa 7, Hisaji Oshima 8, Masato Yagita 9, Yasushi Hiramatsu 10, Norie Yoshikawa 11, Akiko Mitsuo 12, Akira Okamoto 13, Noriyuki Chiba 14, Takao Sugiyama 15, Shouhei Nagaoka 16, Shoji Sugii 17, Keigo Setoguchi 18, Asami Abe 19, Toshiaki Sugaya 20, Masahiro Koseto 21, Yasuo Kunugiza 22, Ryousuke Yoshihara 23, Shinichiro Tsunoda 24, Tomoaki Fujisaki 25, Hiroshi Furukawa 26, Kazuyoshi Saito 27, Kiyoshi Matsui 28, Yasuhiko Tomita 29 and Shigeto Tohma 30, 1National Hospital Organization Osaka Minami Medical Center, Kawachinagano, Osaka, Japan, 2NHO Osaka Minami Medical Canter, Kawachinagano, Osaka, Japan, 3NHO Osaka Minami Medical Center, Kawachinagano, Osaka, Japan, 4National Hospital Organization Nagoya Medical Center, Nagoya, Japan, 5NHO Kyusyu Medical Center, Fukuoka, Japan, 6NHO Sagamihara Hospital, Sagamihara, Japan, 7Osaka Second Police Hospital, Osaka, Japan, 8NHO Tokyo Medical Hospital, Tokyo, Japan, 9Kitano Hospital, Osaka, Japan, 10Japanese Red Cross Society Himeji Hospital, Himeji, Hyogo, Japan, 11NHO Miyakonojo Medical Center, Miyakonojo, Miyazaki, Japan, 12NHO Disaster Medical Center, Tokyo, Tokyo, Japan, 13National Hospital Organization HImeji Medical Center, Himeji, Hyogo, Japan, 14National Hospital Organization Morioka Medical Center, Morioka, Iwate, Japan, 15NHO Shimoshizu Hospital, Chiba, Chiba, Japan, 16Yokohama Minami Kyousai Hospital, Yokohama, Kanagawa, Japan, 17Department of Rheumatic Diseases, Tokyo Metropoitan Tama Medica Center, Fuchu, Japan, 18Tokyo Metropolitan Cancer and Infectious Dease Center Komagome Hospital, Tokyo, Tokyo, Japan, 19Niigata Rheumatic Center, Shibata, Niigata, Japan, 20Fuchu Hospital, Izumi, Osaka, Japan, 21Nippon Life Hospital, Osaka, Osaka, Japan, 22JCHO Hoshigaoka Medical Center, Katano, Osaka, Japan, 23Hyogo Prefecture Kakogawa Hospital, Kakogawa, Hyogo, Japan, 24Sumitomo Hospital, osaka, Osaka, Japan, 25Matsuyama Red Cross Hospital, Matsuyama, Ehime, Japan, 26Molecular and Genetic Epidemiology Laboratory, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan, 27University of Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan, 28Division of Rheumatology, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Japan, 29International University of health and welfare, Narita, Chiba, Japan, 30National Hospital Organization Tokyo National Hospital, Tokyo, Japan

    Background/Purpose: Lymphoproliferative disorders (LPD) remains as a major problem to resolve among the patients with rheumatoid arthritis (RA). During few decades, rheumatic therapy has dramatically…
  • Abstract Number: 514 • 2019 ACR/ARP Annual Meeting

    A Pooled Analysis of 1-year Clinical Outcomes Among 6-month Responders and Non-responders from Three Randomized Controlled Studies of TNF Inhibitor Biosimilars in Patients with Rheumatoid Arthritis

    Josef Smolen1, Michael Weinblatt 2, Paul Emery 3, Jung Yoon Choe 4, Jonathan Kay 5, Jieun Lee 6, Gihyun Myung 6, Hyoryeong Seo 6 and Jeehoon Ghil 6, 1Medical University of Vienna, Vienna, Austria, 2Brigham and Women's Hospital, Boston, MA, 3Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, United Kingdom, 4Division of Rheumatology, Daegu Catholic University Medical Center, Daegu, Republic of Korea, 5UMass Memorial Medical Center and University of Massachusetts Medical School, Worcester, MA, 6Samsung Bioepis Co., Ltd., Incheon, Republic of Korea

    Background/Purpose: SB4, SB2, and SB5 are biosimilars of etanercept, infliximab, and adalimumab. Phase III randomized, double-blind studies were conducted to compare efficacy and safety between…
  • Abstract Number: 1416 • 2019 ACR/ARP Annual Meeting

    B Cell Profile for Early Identification of Optimal Responders to TNF-inhibitors in Rheumatoid Arthritis

    Cristina Sobrino1, Borja Hernández-Breijo 2, Carlota García-Hoz 3, Israel Nieto-Gañán 4, Victoria Navarro-Compán 5, Ana Martínez-Feito 6, javier Bachiller 1, Gema Bonilla 7, Cristina Pijoán-Moratalla 1, Paloma Lapuente-Suanzes 8, Dora Pascual-Salcedo 2, Alejandro Balsa 7, Garbiñe Roy 4, Mónica Vázquez Díaz 1, Luisa María Villar 4, Chamaida Plasencia 7 and Eulalia Rodríguez-Martín 4, 1Rheumatology Department, Ramón y Cajal University Hospital & IRYCIS, Madrid, Spain, 2Immuno-Rheumatology Research Group, IdiPAZ. La Paz University Hospital, Madrid, Spain, 3Immunology Department, Ramón y Cajal University Hospital & IRYCIS, Madrid, 4Immunology Department, Ramón y Cajal University Hospital & IRYCIS, Madrid, Spain, 5University Hospital La Paz, IdiPaz, Madrid, Spain, 6Immuno-Rheumatology Research Group, IdiPAZ & Immunology Department. La Paz University Hospital, MADRID, Spain, 7Immuno-Rheumatology Research Group, IdiPaz & Rheumatology Department. La Paz University Hospital, Madrid, Spain, 8University Hospital Ramón y Cajal, Madrid

    Background/Purpose: Rheumatoid arthritis (RA) is a chronic, inflammatory and heterogeneous autoimmune disorder of unknown etiology characterized by progressive joint damage. Although TNF inhibitors (TNFi) have…
  • Abstract Number: 2371 • 2019 ACR/ARP Annual Meeting

    Risk of Malignancies Across Biologic Classes in Rheumatoid Arthritis: Analysis of a National Claim Database

    Raphaèle Seror1, Alexandre Lafourcade 2, yann De Rycke 2, Bruno Fautrel 3, Xavier Mariette 4 and Florence Tubach 5, 1Université Paris Sud, Hôpitaux Universitaires Paris-Sud, AP-HP, INSERM UMR 1184, Le Kremlin-Bicêtre, France, 2Biostatistics, Public Health and Medical Information department, Pitié-Salpêtrière Hospital, AP-HP, Paris, France, Paris, France, 3Pitié-Salpêtrière Hospital, Department of Rheumatology, AP-HP, Sorbonne University, UPMC university, Paris, Ile-de-France, France, 4Center for Immunology of Viral Infections and Autoimmune Diseases, Assistance Publique – Hôpitaux de Paris, Hôpitaux Universitaires Paris-Sud, Le Kremlin-Bicêtre, Université Paris Sud, INSERM, Paris, France, 5Pitié Salpétrière University-Hospital, Paris, Ile-de-France, France

    Background/Purpose: Our objectives were to estimate and compare the incidence rate of malignancies associated with the different classes of biologics in RA patients.Methods: We conducted…
  • Abstract Number: 526 • 2019 ACR/ARP Annual Meeting

    Factors Influencing Discontinuation in Long-term RA Treatment

    Madison Grinnell1, Sofia Pedro 2 and Kaleb Michaud 3, 1University of Nebraska College of Medicine, OMAHA, NE, 2FORWARD, The National Databank for Rheumatic Diseases, Wichita, KS, 3University of Nebraska Medical Center, Omaha, NE

    Background/Purpose: While medication persistence can act as a substitute metric for effectiveness, few studies have examined real-world patterns of bDMARD persistence by line of treatment…
  • Abstract Number: 1441 • 2019 ACR/ARP Annual Meeting

    Is Background Methotrexate Still Advantageous in Extending TNF Drug Survival in the Elderly: An Analysis of the British Society for Rheumatology Biologics Register – Rheumatoid Arthritis

    Katie Bechman1, Anuoluwapo Oke 2, Mark Yates 3, Sam Norton 3, Elaine Denderson 4, Andrew Cope 5 and James Galloway 2, 1Kings College London, London, England, United Kingdom, 2Kings College London, London, United Kingdom, 3Kings College London, London, 4MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, 5Academic Rheumatology, King's College London, London, United Kingdom

    Background/Purpose: Long-term observational data from national registries in rheumatoid arthritis allow the examination of TNF drug survival rates. Despite a good initial response to a…
  • Abstract Number: 2391 • 2019 ACR/ARP Annual Meeting

    Effect of Biologics on the Hemoglobin A1c in a Population of Rheumatoid Arthritis Patients

    Ana Goico 1, Anoka Martis1, Chistopher Kabir 1, David Mael 1 and Shoeb Mohammed 1, 1Advocate Illinois Masonic Medical Center, Chicago, IL

    Background/Purpose: Tumor necrosis factor (TNF), a pathogenic inflammatory mediator in Rheumatoid Arthritis (RA), has been shown to play an essential role in the pathophysiology of insulin resistance.…
  • Abstract Number: 549 • 2019 ACR/ARP Annual Meeting

    US Rheumatologists’ Beliefs and Knowledge About Biosimilars – an Ongoing Survey

    Allan Gibofsky1, Dorothy McCabe 2 and Sam Badawi 2, 1Weill Cornell Medical College, New York, NY, 2Boehringer Ingelheim, Ridgefield, CT

    Background/Purpose: A systematic review of survey literature from 2014-2018 found that clinicians in the US and Europe are cautious about biosimilar use (JMCP; 2019;25:102). We…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 29
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology